Daily Cosmetic Research Analysis
Analyzed 19 papers and selected 3 impactful papers.
Summary
Three papers stood out today: a mechanistic nanomedicine study shows hydroxyl-terminated PEG evades pre-existing anti-PEG antibodies, a photothermal biomaterial scaffold co-delivering corynoline and EVs accelerates vascularized bone regeneration, and a PRISMA-compliant meta-analysis finds minimally invasive cardiac surgery yields superior scar outcomes versus full sternotomy. Collectively, they advance cosmetic outcomes, material immunocompatibility, and regenerative aesthetics.
Research Themes
- Immunogenicity mitigation in PEGylated materials
- Photothermal biomaterials enabling vascularized bone regeneration
- Scar aesthetics and patient-reported outcomes in cardiac surgery
Selected Articles
1. Hydroxyl-Terminated Polyethylene Glycol Evades Human Pre-existing Anti-polyethylene Glycol Antibodies.
In 1,970 human samples, pre-existing anti-PEG IgM binding was strongly influenced by PEG terminal chemistry: methoxy end-groups enhanced binding, whereas hydroxyl-terminated PEG largely evaded it. Substituting MeO-PEG with OH-PEG in LNPs attenuated complement activation, improved serum stability, reduced mRNA leakage, and lowered immunogenicity, highlighting a practical path to safer repeat dosing.
Impact: Defines a clear, actionable materials-chemistry lever (terminal group) to mitigate clinically relevant anti-PEG responses using large-scale human data and functional LNP assays.
Clinical Implications: Consider screening for anti-PEG antibodies and preferentially using OH-PEG over MeO-PEG in PEGylated nanomedicine design to reduce complement activation and hypersensitivity, especially for repeated dosing regimens.
Key Findings
- In 1,970 human samples, methoxy terminal groups increased binding of pre-existing anti-PEG IgM to PEG.
- Hydroxyl-terminated PEG (OH-PEG) largely evaded binding by pre-existing anti-PEG IgM across three hospitals.
- Replacing MeO-PEG with OH-PEG in LNPs attenuated complement activation, enhanced serum stability, and reduced mRNA leakage.
- OH-PEG-modified LNPs exhibited reduced immunogenicity, supporting safer repeat administrations; current interspecies preclinical models underrepresent human anti-PEG biology.
Methodological Strengths
- Large human cohort (n=1970) spanning three independent hospitals
- Mechanistic linkage of PEG terminal chemistry to antibody binding with functional readouts (complement activation, mRNA leakage) in human serum
Limitations
- Primarily focuses on anti-PEG IgM; clinical outcome correlations are indirect
- Translational performance in diverse formulations and long-term safety not established
Future Directions: Prospective clinical studies linking OH-PEG formulations to reduced infusion reactions; standardized human-serum assays for preclinical screening; exploration of terminal chemistries beyond OH/MeO for optimized stealth.
Polyethylene glycol (PEG) has been extensively utilized in food, cosmetics, and pharmaceutical fields, especially in the realm of nanomedicines, where it serves as a pivotal excipient to prolong the nanoparticles' circulation half-life. Contrary to its historical perception as being nonimmunogenic, pre-existing anti-PEG antibodies have been widely detected in human even in individuals without prior exposure to PEGylated therapeutics and are associated with clinically relevant adverse effects of PEGylated nanomedicines including infusion reactions and hypersensitive reactions. Herein, we elucidated the prevalence and distribution characteristics of pre-existing anti-PEG antibodies in 1970 human blood samples and investigated its binding with PEG. The binding between pre-existing anti-PEG IgM and PEG was modulated by PEG terminal chemistry, with methoxy groups enhancing overall antibody-PEG interactions. Notably, methoxy is the only terminal configuration used in currently marketed PEGylated nanomedicines. In contrast, hydroxy PEG (OH-PEG) significantly evaded binding with pre-existing anti-PEG IgM among most clinical samples from three independent hospitals. Noteworthily, replacing methoxy PEG (MeO-PEG) with OH-PEG significantly attenuated complement activation of lipid nanoparticle (LNP) caused by pre-existing anti-PEG IgM, thereby markedly enhancing stability and reducing mRNA leakage in human serum. Additionally, LNP modified with OH-PEG exhibited reduced immunogenicity, which is crucial for repeated administrations. Collectively, this study elucidated the crucial role of OH-PEG in evading human pre-existing anti-PEG antibodies and discovered that the current preclinical studies inadequately simulated the biological effects of clinical pre-existing anti-PEG antibodies on such formulations through interspecies study, which had a profound impact on clinical translation of PEGylated nanomedicines.
2. Corynoline and Extracellular Vesicles Co-Loaded Scaffold Accelerates Vascularized Bone Regeneration with Photothermal Stimulation.
A β-TCP/polydopamine scaffold co-loaded with corynoline and osteogenic EVs releases bioactive cues under NIR-induced photothermal control for ≥14 days, shifting macrophages to M2 and boosting angiogenesis/osteogenesis. In vivo, the platform reduced inflammation and enhanced vascularized bone formation, suggesting a translatable immuno-regenerative strategy.
Impact: Integrates immune modulation and angiogenic osteogenesis into a single NIR-tunable scaffold with in vivo validation, addressing a central barrier to large defect reconstruction.
Clinical Implications: Points toward controllable, minimally invasive adjuvant therapy for craniofacial and long-bone defects, potentially improving cosmetic contour and function while reducing donor-site morbidity.
Key Findings
- Developed a β-TCP/PDA scaffold co-loaded with corynoline and osteogenic EVs, enabling NIR-triggered, sustained release for at least 14 days.
- Corynoline promoted macrophage polarization from M1 to M2 and reduced ROS; EVs enhanced angiogenesis and osteogenesis.
- Under NIR stimulation, the scaffold modulated the immune microenvironment and significantly increased vascularized bone regeneration in vivo with reduced inflammation and enhanced cell recruitment.
Methodological Strengths
- Multimodal design combining immunomodulation and pro-angiogenic cues with NIR-controlled release
- In vivo validation demonstrating enhanced bone formation and vascularization
Limitations
- Preclinical, likely small-animal models; long-term safety, biodegradation, and dosing regimens remain to be established
- Clinical feasibility of NIR delivery and heat dosing in deep defects is uncertain
Future Directions: Scale-up studies in large-animal critical defects, long-term biocompatibility/degradation profiling, and clinical protocols for NIR dosing and monitoring.
Bone defect repair remains a major clinical challenge, and effective alternatives to autologous bone grafting are urgently needed due to limitations such as donor site scarcity, immune complications, and high long-term resorption rates. In this study, we developed a near-infrared (NIR)-responsive composite scaffold for the controlled and sustained delivery of corynoline (Cor) and extracellular vesicles (EVs) to enhance bone regeneration. The scaffold was constructed from β-tricalcium phosphate (β-TCP) and coated with bioinspired polydopamine (PDA), which enabled efficient immobilization of Cor and EVs via surface adsorption. The PDA layer endowed the scaffold with photothermal properties, allowing NIR irradiation to trigger and accelerate the release of bioactive factors in a sustained manner for at least 14 days. Cor promoted macrophage polarization from the pro-inflammatory M1 phenotype toward the anti-inflammatory M2 phenotype, thereby reducing excessive reactive oxygen species, while EVs derived from osteogenically induced umbilical cord mesenchymal stem cells enhanced angiogenesis and osteogenesis. The photothermal effect of PDA further synergized with these biofactors to modulate the local microenvironment. Under NIR stimulation, the composite scaffold effectively regulated the immune microenvironment and promoted vascularized bone regeneration. In vivo results demonstrated significantly enhanced new bone formation, accompanied by reduced inflammation, increased endogenous cell recruitment, and accelerated vascularization. Overall, this multifunctional, NIR-responsive scaffold provides a promising strategy for efficient and controlled bone defect repair.
3. Scar-specific outcomes following minimally invasive versus conventional median sternotomy in cardiac surgery: A systematic review and meta-analysis.
Across 22 studies (n=3,131), minimally invasive cardiac surgery achieved significantly better validated scar assessment scores than full sternotomy. The synthesis emphasizes cosmetic, patient-centered outcomes in addition to traditional metrics, supporting shared decision-making.
Impact: Provides the first focused meta-analytic synthesis of scar-specific outcomes comparing MICS vs. sternotomy, quantifying the aesthetic advantage with validated instruments.
Clinical Implications: When clinically appropriate, MICS may be preferred to improve cosmetic scar outcomes without compromising surgical goals; counseling should include scar expectations using validated scales.
Key Findings
- Meta-analysis of 22 studies involving 3,131 adults showed MICS yielded significantly better scar assessment scores than full sternotomy (SMD -0.74; p<0.01).
- Patient-reported cosmetic outcomes and scar-specific metrics were the primary endpoints, following PRISMA methodology.
- Search spanned multiple databases (PubMed, Embase, CENTRAL, Scopus) with random-effects modeling.
Methodological Strengths
- PRISMA-compliant systematic review and meta-analysis with validated scar instruments
- Large pooled sample size enabling precise effect estimates
Limitations
- Heterogeneity in MICS techniques and scar assessment tools across studies
- Potential residual confounding from non-randomized designs within included studies
Future Directions: Prospective, standardized comparative studies (ideally RCTs) assessing scar outcomes and patient satisfaction with harmonized instruments and long-term follow-up.
BackgroundWith improved cardiac surgical outcomes, attention has shifted to patient-centred outcomes, including cosmetic appearances of surgical scars. Minimally invasive cardiac surgery (MICS) is often promoted for its cosmetic benefits, yet empirical evidence remains limited. This study aimed to systematically evaluate scar-specific outcomes comparing MICS to conventional full median sternotomy (FMS) in adult cardiac surgery.MethodsA systematic review and meta-analysis was conducted following PRISMA guidelines. PubMed, Embase, Central, and Scopus were searched from inception to August 2025. Studies comparing MICS to FMS, reporting scar-related patient-reported outcomes, wound complications, or cosmetic satisfaction, were included. The primary outcome was scar assessment using validated instruments. Random-effects models calculated standardised mean differences (SMD) and risk ratios (RR) with 95% confidence intervals.ResultsTwenty-two studies comprising 3131 patients (1459 MICS, 1672 FMS) met inclusion criteria. MICS demonstrated significantly better scar assessment scores (SMD -0.74, 95% CI -1.27 to -0.22; p < 0.01; I